Erratum: Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis (Journal of Gastroenterology and Hepatology DOI: 10.1111/j.1440-1746.2006.04735.x);Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 11, 2007, Pages 2022-2033

  Kitamura, Kumi ^a   Tada, Shinichiro ^a   Nakamoto, Nobuhiro ^a   Toda, Kyoko ^b   Horikawa, Hitomi ^a   Kurita, Satoshi ^a   Tsunematsu, Satoshi ^b   Kumagai, Naoki ^b   Ishii, Hiromasa ^a   Saito, Hidetsugu ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY   (Japan)

^b KITASATO INSTITUTE HOSPITAL   (Japan)

Author keywords

Free radical; Hepatic fibrosis; Hepatic stellate cells; Renin angiotensin system; Rho Rho kinase system

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; ALPHA SMOOTH MUSCLE ACTIN; AMINO ACID; ANGIOTENSIN II; CANDESARTAN; CANDESARTAN HEXETIL; RHO KINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL COUNT; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; FATTY LIVER; FIBROGENESIS; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER FIBROSIS; LIVER HISTOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STELLATE CELL;

EID: 34948841930     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04920.x     Document Type: Erratum

References (56)

1. Ghany MG, Kleiner DE, Alter H et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003 124 : 97 104.
2. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004 53 : 744 9.
3. Leone N, Baronio M, Todros L et al. Hepatic involvement in larva migrans of Toxocara canis: report of a case with pathological and radiological findings. Dig. Liver Dis. 2006 38 : 511 14.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002 347 : 975 82.
5. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
6. Iwasaki Y, Ikeda H, Araki Y et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006 43 : 54 63.
7. Mann DA, Smart DE. Transcriptional regulation of hepatic stellate cell activation. Gut 2002 50 : 891 6.
8. Eng FJ, Friedman SL, Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. Am. J. Physiol. Gastrointest. Liver Physiol. 2000 279 : G7 11.
9. Ohishi T, Saito H, Tsusaka K et al. Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol. Res. 2001 21 : 147 58.
10. Kurikawa N, Suga M, Kuroda S, Yamada K, Ishikawa H. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br. J. Pharmacol. 2003 139 : 1085 94.
11. Garcia-Pagan JC, Bosch J, Rodes J. The role of vasoactive mediators in portal hypertension. Semin. Gastrointest. Dis. 1995 6 : 140 7.
12. Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 1999 19 : 1623 9.
13. Schnee JM, Hsueh WA. Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc. Res. 2000 46 : 264 8.
14. Kawano H, Do YS, Kawano Y et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000 101 : 1130 7.
15. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J. Clin. Invest. 1994 93 : 2431 7.
16. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J. Hypertens. 2002 20 : 965 73.
17. Ahmed MS, Oie E, Vinge LE et al. Connective tissue growth factor - a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats. J. Mol. Cell Cardiol. 2004 36 : 393 404.
18. Ruperez M, Ruiz-Ortega M, Esteban V et al. Angiotensin II increases connective tissue growth factor in the kidney. Am. J. Pathol. 2003 163 : 1937 47.
19. Takeda K, Ichiki T, Tokunou T et al. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler. Thromb. Vasc. Biol. 2001 21 : 868 73.
20. Schmitz U, Ishida T, Ishida M et al. Angiotensin II stimulates p21-activated kinase in vascular smooth muscle cells: role in activation of JNK. Circ. Res. 1998 82 : 1272 8.
21. Morita N, Iizuka K, Murakami T, Kawaguchi H. N-terminal kinase, and c-Src are activated in human aortic smooth muscle cells by pressure stress. Mol. Cell Biochem. 2004 262 : 71 8.
22. Rikitake Y, Liao JK. ROCKs as therapeutic targets in cardiovascular diseases. Exp. Rev. Cardiovasc. Ther. 2005 3 : 441 51.
23. Kobayashi N, Nakano S, Mita S et al. Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats. J. Pharmacol. Exp. Ther. 2002 301 : 459 66.
24. Uehata M, Ishizaki T, Satoh H et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997 389 : 990 4.
25. Satoh S, Ueda Y, Koyanagi M et al. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J. Mol. Cell Cardiol. 2003 35 : 59 70.
26. Ananthanarayanan V, Pins MR, Meyer RE, Gann PH. Immunohistochemical assays in prostatic biopsies processed in Bouin's fixative. J. Clin. Pathol. 2005 58 : 322 4.
27. Tada S, Saito H, Tsunematsu S et al. Interferon regulatory factor-1 gene abnormality and loss of growth inhibitory effect of interferon-alpha in human hepatoma cell lines. Int. J. Oncol. 1998 13 : 1207 16.
28. Liu J, Lei D, Waalkes MP, Beliles RP, Morgan DL. Genomic analysis of the rat lung following elemental mercury vapor exposure. Toxicol. Sci. 2003 74 : 174 81.
29. Nakao A, Moore BA, Murase N et al. Immunomodulatory effects of inhaled carbon monoxide on rat syngeneic small bowel graft motility. Gut 2003 52 : 1278 85.
30. Friedman SL, Roll FJ. Isolation and culture of hepatic lipocytes, Kupffer cells, and sinusoidal endothelial cells by density gradient centrifugation with Stractan. Anal. Biochem. 1987 161 : 207 18.
31. Tsutsumi M, Takada A, Takase S. Characterization of desmin-positive rat liver sinusoidal cells. Hepatology 1987 7 : 277 84.
32. Tahashi Y, Matsuzaki K, Date M et al. Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 2002 35 : 49 61.
33. Schneider E, Schmid-Kotsas A, Zhao J et al. Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells. Am. J. Physiol. Cell Physiol. 2001 281 : C532 43.
34. Nakae D. Endogenous liver carcinogenesis in the rat. Pathol. Int. 1999 49 : 1028 42.
35. Hironaka K, Sakaida I, Uchida K, Okita K. Correlation between stellate cell activation and serum fibrosis markers in choline-deficient 1-amino acid-defined diet-induced rat liver fibrosis. Dig. Dis. Sci. 2000 45 : 1935 43.
36. Wu J, Zern MA. Hepatic stellate cells: a target for the treatment of liver fibrosis. J. Gastroenterol. 2000 35 : 665 72.
37. Yamakawa T, Tanaka S, Numaguchi K et al. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 2000 35 : 313 18.
38. Fukushima M, Nakamuta M, Kohjima M et al. Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int. 2005 25 : 829 38.
39. Ikeda H, Nagashima K, Yanase M et al. Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2003 285 : G880 6.
40. Tada S, Iwamoto H, Nakamuta M et al. A selective ROCK inhibitor, Y-27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J. Hepatol. 2001 34 : 529 36.
41. Oliveira CP, da Costa Gayotto LC, Tatai C et al. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. J. Cell Mol. Med. 2002 6 : 399 406.
42. Oliveira CP, Gayotto LC, Tatai C et al. Vitamin C and vitamin E in prevention of nonalcoholic fatty liver disease (NAFLD) in choline deficient diet fed rats. Nutr. J. 2003 2 : 9.
43. Tomita K, Tamiya G, Ando S et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006 55 : 415 24.
44. Nakamoto N, Tada S, Kameyama K et al. A free radical scavenger, edaravone, attenuates steatosis and cell death via reducing inflammatory cytokine production in rat acute liver injury. Free Radic. Res. 2003 37 : 849 59.
45. Tada S, Nakamoto N, Kameyama K et al. Clinical usefulness of edaravone for acute liver injury. J. Gastroenterol. Hepatol. 2003 18 : 851 7.
46. Bataller R, Gabele E, Schoonhoven R et al. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am. J. Physiol. Gastrointest. Liver Physiol. 2003 285 : G642 51.
47. Cediel E, Sanz-Rosa D, Oubina MP et al. Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function? Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003 285 : R674 81.
48. Guo L, Richardson KS, Tucker LM, Doll MA, Hein DW, Arteel GE. Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats. Hepatology 2004 40 : 583 9.
49. Svegliati-Baroni G, Saccomanno S, van Goor H, Jansen P, Benedetti A, Moshage H. Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver 2001 21 : 1 12.
50. Bataller R, Schwabe RF, Choi YH et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Invest. 2003 112 : 1383 94.
51. Bataller R, Sancho-Bru P, Gines P et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003 125 : 117 25.
52. Okuno M, Moriwaki H, Imai S et al. Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-beta in liver stellate cells. Hepatology 1997 26 : 913 21.
53. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006 43 : S99 S112.
54. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient 1-amino acid-defined diet. Biochem. Biophys. Res. Commun. 2004 315 : 187 95.
55. Sanyal AJ. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005 2 : 46 53.
56. Yokohama S, Yoneda M, Haneda M et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004 40 : 1222 5.